Viking Therapeutics, Inc. (NASDAQ:VKTX) Q3 2023 Earnings Call Transcript

Page 4 of 4

Thomas Smith: Got it, understood. Thanks for taking the questions, guys.

Brian Lian: Thanks, Tom.

Operator: [Operator Instructions] Our next question comes from Yale Jen of Laidlaw & Company. Please go ahead.

Yale Jen: Good afternoon and thanks for taking the question. Again, on the obesity week data, just curious that if the VENTURE data also looks good, does the obesity, I’m sorry, the obesity week data in the plasma lipid as well as in the statin lipid, would impact on your potential future, let’s say Phase 3 study in terms of selecting more sub-cohort of the obesity patients or that’s not necessarily into consideration?

Brian Lian: Not in consideration at this point. I think the plasma lipid effects were really interesting in that they might allow you to reduce the dose of a statin or something like that. So that was a really neat finding. And it was kind of across the board there. We saw a nice reductions in plasma lipids. But for now, the VENTURE Study will be a pure obesity study. It is a pure obesity study. And we anticipate the subsequent studies to really focus on obesity and not any subsets at this point.

Yale Jen: Okay, great. Just one more question here. In terms again, in 2735, first of all do you guys have any specific injectors used in the study? And how do you see that in the future that at least currently there’s some shortage issues? What’s your thoughts?

Brian Lian: Yes, yes. Fortunately we have some time to work through that. And we are looking at sort of the early models of injectors. This trial is a vial and syringe trial where people are dosed in the clinic. But the next studies we would anticipate to use some form of an auto-injector.

Yale Jen: Okay, great. And congrats on all the progress and look forward to readout early next year.

Brian Lian: Thanks, Yale.

Operator: Our next question comes from Justin Zelin of BTIG. Please go ahead.

Justin Zelin: Hey, Brian. Congrats on the progress here. Just wanted to ask you’ve seen promising data from both 2809 and 2735. Just wanted to hear your current thoughts on a potential study using both agents in the treatment of NASH. And then just a quick follow-up.

Brian Lian: Yes thanks, Justin. We spent a lot of time on that thinking about how these could be combined. They’re different formulations. And so the up-front formulation work is a little more extensive if we were to pursue a combination agent. And then the other requirements on tox [Ph] is also, it’s just different with two unapproved agents. So more extensive on that front as well. So I think it’s a really potentially high-value combination. But we don’t have anything to say further about it right now. I think it could be very useful though in the future.

Justin Zelin: Right. That makes sense to me. And then you’re developing both an oral and an injectable. Maybe just to hear your current thoughts on how that market might evolve. Obviously with multiple modalities, do you think patients might start in an injectable and then move to an oral for maintenance?

Brian Lian: Yes. We view them as different products, really. The option you mentioned where somebody maybe doesn’t want to start with an injectable because they feel like it’s a little more intensive or intrusive, whatever starting with an oral and seeing some weight loss might lower the resistance to start using injectable. So that’s one option. The other would be the flip side where someone who’s lost a lot of weight on an injectable might want to transition to an oral and so for more of a maintenance, longer-term usage. That’s another great opportunity. And then the other big bucket we think about is, temporary use. Somebody wants to lose some weight for summer or an upcoming event or something like that. I think there would be a great opportunity there. So the oral does not need the same efficacy as the sub-Q because the uses will likely be different. So I think they’re nicely complementary products and have completely complementary areas of application.

Justin Zelin: Great. That makes sense to me. Thanks for taking my questions.

Brian Lian: Thanks, Justin.

Operator: This concludes our question-and-answer session. I would like now to turn the conference back over to Stephanie Diaz for any closing remarks.

Stephanie Diaz: Thank you again for your participation and continued support of Viking Therapeutics. We look forward to updating you again in the coming months. Have a good afternoon.

Operator: The conference has now concluded. Thank you for attending today’s presentation. You may now disconnect.

Follow Viking Therapeutics Inc. (NASDAQ:VKTX)

Page 4 of 4